SynopsisDr. Reddy's Laboratories has finalized its acquisition of the Stugeron brand from Johnson & Johnson, encompassing EMEA regions, India, and Vietnam. This strategic move allows Dr. Reddy's to broaden its presence in the anti-vertigo market and reinforce its Central Nervous System portfolio. The company aims to extend Stugeron's reach across 18 key markets, aligning with its goal of reaching 1. ...

The transaction covers 18 markets across APAC and EMEA, with India and Vietnam identified as focus geographies. Stugeron, which contains the antihistamine Cinnarizine, is prescribed for vestibular disorders and vertigo.In India, the brand leads the Cinnarizine-represented pharmaceutical market (RPM) and ranks second in the broader anti-vertigo represented pharmaceutical market (eRPM). The deal will help Dr. Reddy’s strengthen its Central Nervous System (CNS) portfolio and expand in the anti-vertigo space.“ ...

Dr. Reddy’s Laboratories Ltd. on Thursday announced a deal with Johnson & Johnson affiliate Janssen Pharmaceutica NV to acquire its anti-vertigo drug under the 'Stugeron' brand for $50.5 million or Rs 445 crore. The local drugmaker will acquire the 'Stugeron' brand, including its key local brands Stugeron FORTE and Stugeron PLUS, as well as its related assets across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions, with India and Vietnam as key markets, according to a ...